ArticleThe Lancet regional health. Europe2026
Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correspondence About the Paper "Effectiveness of High-Dose Influenza Vaccine Against Hospitalisations in Older Adults (FLUNITY-HD): An Individual Level Pooled Analysis" by Niklas Dyrby Johansen et al., https://doi.org/10.1016/S0140-6736(25)01742-8.Influenza and other respiratory viruses · 2026Article
- Feasibility of conducting brand-specific influenza vaccine effectiveness studies in three Nordic countries, Denmark, Finland, Sweden.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Seasonal influenza causes substantial morbidity and mortality in older adults. While vaccination is recommended in Nordic countries for individuals aged ≥65 years, brand-specific effectiveness estimates are scarce but essential for regulatory decision-making. We evaluated brand-specific effectiveness of seasonal influenza vaccines against laboratory-confirmed influenza-related outcomes in Denmark, Finland, and one Swedish region during the 2024/2025 season. Methods: We conducted a nationwide cohort study using target trial emulation and linked health registries. Individuals aged ≥65 years were matched 1:1, comparing seasonal influenza vaccine recipients to non-recipients. Cumulative incidences of laboratory-confirmed influenza A and B, influenza-related hospitalisation, and death were assessed at 18 weeks post-immunisation. Vaccine effectiveness (VE) was calculated as 1 minus the risk ratio. Findings: A total of 1,164,686 matched pairs were included (mean age 75.4 years, standard deviation 7.3). Overall VE against influenza-related hospitalisation was 46.8% (95% CI 40.8-52.9), with risk differences of -21.3 (-28.9 to -13.8) and -99.3 (-119.6 to -79.1) in Finland and Denmark, respectively, per 100,000 vaccinated individuals. Brand-specific VE was 63.4% (38.1-88.7) for Efluelda Tetra (split virion-high dose), 48.2% (40.8-55.6) for Fluad Tetra (subunit standard-dose adjuvanted), 43.6% (23.7-63.6) for Vaxigrip Tetra (split virion standard-dose), and 30.6% (-7.8 to 69.1) for Influvac Tetra (subunit standard-dose). VE waned by -6.5 percentage points (-10.5 to -2.5) every 3 weeks. Interpretation: Seasonal influenza vaccines moderately reduced the risk of severe outcomes in older adults. Efluelda Tetra and Fluad Tetra appeared to offer favourable protection in their respective target groups, supporting their use in the 2025/2026 season. Annual monitoring using Nordic registries is crucial for informing evidence-based vaccination strategies and regulatory decisions. Funding: European Medicines Agency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.